Ascentage Pharma Company

Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Leveraging their expertise in structure-based drug design and their innovative drug discovery engine, we have developed a robust pipeline of seven drug candidates that disrupt complex and difficult-to-target protein-protein interactions (PPIs), and next-generation tyrosine kinase inhibitors (TKIs). Their PPI drug candidates are designed to treat cancer and other diseases by restoring the normal function of key apoptotic pathways, including the Bcl-2/Bcl-xL, MDM2-p53 and IAP pathways, which play a pivotal role in regulating apoptosis. They are also developing next-generation TKIs to treat diseases for high unmet medical needs. Their compounds are being developed for use as a single agent or in combination with other therapies.
Technology: Geroscience
Industry: Biotechnology, Health Care, Science and Engineering
Headquarters: Suzhou, Jiangsu, China
Founded Date: 1-1
Employees Number: 101-250
Funding Status: Late Stage Venture
Investors Number: 13
Total Funding: 237486984
Estimated Revenue: $10M to $50M
Last Funding Date: 2018-07-17
Last Funding Type: Series C

Visit Website
bd@ascentagepharma.com
Register and Claim Ownership